3 active not recruiting. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Dermatomyositis: new trials by email Literature Review of Dermatomyositis trials Research Report on Dermatomyositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Rapcabtagene Autoleucel in Myositis Rapcabtagene autoleucel, Active Comparator Option - Idiopathic Inflammatory Myopathies | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 21 | 2024-12-17 | 2026-06-23 |
| A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis Empasiprubart IV, Placebo IV - Dermatomyositis, Myositis | Phase 2 | Active not recruiting | argenx | 3 | 2024-08-20 | 2026-11-04 |
| Add-on Intravenous Immunoglobulins in Early Myositis Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis | Phase 2 / Phase 3 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 44 | 2021-09-13 | 2026-02-27 |
Myositis (3) · Antisynthetase syndrome (1) · Lung Diseases, Interstitial (1) · Polymyositis (1)
Connective Tissue Diseases (3) · Muscular Diseases (3) · Musculoskeletal Diseases (3) · Nervous System Diseases (3) · Neuromuscular Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Polymyositis (2) · Lung Diseases (1) · Respiratory Tract Diseases (1)
Immunoglobulins, Intravenous (1) · Sodium Chloride (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Novartis Pharmaceuticals (1) · argenx (1)
Italy (2) · Netherlands (2) · Spain (2) · United States (2) · Australia (1) · Brazil (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Israel (1) · Japan (1) · Moldova (1) · Poland (1) · Saudi Arabia (1)
2023 (1)